EASTMAN CHEMICAL CO
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Sales by Customer Location
| Sales Revenue | ||||||||
|---|---|---|---|---|---|---|---|---|
| Third Quarter · First Nine Months | ||||||||
| Change | Change | |||||||
| (Dollars in millions) | 2026 | 2025 | $ | % | 2026 | 2025 | $ | % |
| United States and Canada | $1,094 | $972 | $122 | 13% | $3,231 | $2,955 | $276 | 9% |
| Europe, Middle East, and Africa | 609 | 563 | 46 | 8% | 1,811 | 1,783 | 28 | 2% |
| Asia Pacific | 535 | 534 | 1 | —% | 1,613 | 1,656 | (43) | (3)% |
| Latin America | 147 | 133 | 14 | 11% | 420 | 385 | 35 | 9% |
| Total Eastman | $2,385 | $2,202 | $183 | 8% | $7,075 | $6,779 | $296 | 4% |
Sales revenue increased 8 percent in third quarter 2026 compared to third quarter 2025. Higher sales revenue was due to higher selling prices across all regions except the Asia Pacific region and higher sales volume across all regions.
Sales revenue increased 4 percent in first nine months 2026 compared to first nine months 2025. Higher sales revenue was primarily due to higher selling prices and higher sales volume in the United States and Canada and Latin America regions, as well as a favorable foreign currency exchange impact in the Europe, Middle East, and Africa ("EMEA") and Asia Pacific regions. These increases were partially offset by lower selling prices in the Asia Pacific region and lower sales volume in the EMEA region.
Further discussion by operating segment is presented in "Summary by Operating Segment" in this MD&A.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.